Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Guang-Liang Chen, Jia Jin, Hui Sun, Yizhen Liu, Qunling Zhang, Zuguang Xia, Junning Cao, Xiaonan Hong, Fangfang Lv

Blood (2024) 144 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2024-194111

Published: 2024

Journal Articles

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Guangliang Chen, Kai Xue, Qunling Zhang, Jia Jin, Yizhen Liu, Zuguang Xia, Fangfang Lyu, Xiaonan Hong, Xiaoqiu LI, Junning Cao

Blood (2023) 142 (Supplement 1): 5805.

https://doi.org/10.1182/blood-2023-174307

Published: 2023

Journal Articles

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Guang-Liang Chen, Pin Guo, Shiyu Jiang, Juan J. Gu, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Rong TAO, Fangfang Lv

Blood (2022) 140 (Supplement 1): 3790–3791.

https://doi.org/10.1182/blood-2022-156877

Published: 2022

Journal Articles

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Yizhen Liu, Qunling Zhang, Fangfang Lv, Xiaojian Liu, Dongmei Ji, Zuguang Xia, Jia Jin, Rong TAO, Wenhao Zhang, Xiaoqiu Li, Shengjian Zhang, Jiachen Wang, Xiaonan Hong, Junning Cao

Blood (2022) 140 (Supplement 1): 6627–6628.

https://doi.org/10.1182/blood-2022-158657

Published: 2022

Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood (2021) 138 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2021-149861

Published: 2021

Journal Articles

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Juan J Gu, Paola Ghione, Shiyu Jiang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Dongmei Ji, Junning Cao, Xiaonan Hong, Xuejun Ma, Qunling Zhang

Blood (2021) 138 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2021-149229

Published: 2021

Journal Articles

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Qunling Zhang, Jichuan Wu, Juan J. Gu, Yizhen Liu, Zuguang Xia, Lan Wang, Xiaonan Hong, Junning Cao

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141887

Published: 2020

Journal Articles

Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Xiangnan Jiang, MD, Wanhui Yan, Yifeng Sun, Qinghua Xu, Xiaoyan Zhou, MD, Junning Cao, Xiaonan Hong, Xiaoqiu Li

Blood (2019) 134 (Supplement_1): 5337.

https://doi.org/10.1182/blood-2019-126629

Published: 2019

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai

Blood (2019) 133 (2): 137–146.

https://doi.org/10.1182/blood-2018-04-848044

Published: 2019

Includes: Supplemental data

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Zuguang Xia, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Ye Guo, Xiaonan Hong, Junning Cao, MD

Blood (2018) 132 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2018-99-118872

Published: 2018

Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 784.

https://doi.org/10.1182/blood-2018-99-112988

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 824.

https://doi.org/10.1182/blood.V130.Suppl_1.824.824

Published: 2017

Journal Articles

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Shigeru Kusumoto, MD, Luca Arcaini, MD, Xiaonan Hong, Jie Jin, Won Seog Kim, MD, Ph. D., Yok Lam Kwong, Marion Peters, Yasuhito Tanaka, Andrew D. Zelenetz, MD PhD, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai, MD PhD

Blood (2017) 130 (Supplement 1): 2823.

https://doi.org/10.1182/blood.V130.Suppl_1.2823.2823

Published: 2017

Journal Articles

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Junning Cao, Xiaonan Hong, Ye Guo

Blood (2017) 130 (Supplement 1): 2839.

https://doi.org/10.1182/blood.V130.Suppl_1.2839.2839

Published: 2017

Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Blood (2016) 128 (22): 470.

https://doi.org/10.1182/blood.V128.22.470.470

Published: 2016

Journal Articles

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Yuankai Shi, MD PhD, Mei Dong, MD, Jun Zhu, MD, Daobin Zhou, MD, Huiqiang Huang, MD, Ping Tu, MD, Weijing Zhang, MD, Xiaonan Hong, MD, Xielan Zhao, MD, Jianfang Sun, MD, Yuehua Liu, MD, Lugui Qiu, MD PhD, ZhiXiang Shen, MD, Jifeng Feng, MD, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 1513.

https://doi.org/10.1182/blood.V126.23.1513.1513

Published: 2015

Journal Articles

Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568

Kai Xue, MD, Juan J Gu, PhD, Qunling Zhang, MD, Xiaojian Liu, MD, Jiachen Wang, Jianfeng Luo, Francisco J. Hernandez-Ilizaliturri, MD, Stanley F. Fernandez, MD, Myron S. Czuczman, MD, Junning Cao, MD Associate Professor, Xiaonan Hong, MD, Ye Guo, MD

Blood (2014) 124 (21): 3041.

https://doi.org/10.1182/blood.V124.21.3041.3041

Published: 2014

NARROW

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only